Natriuretic peptides and nitric oxide play important roles in cardiovascular and renal physiology and disease. The natriuretic peptides -atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide -comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure. The natriuretic peptides differentially bind distinct classes of receptors that signal through different mechanisms. Membrane-bound, guanylyl cyclase-coupled natriuretic peptide receptors (A-and B-types) mediate natriuretic peptide effects through the production of 39,59-cyclic guanosine monophosphate (cGMP). C-Type natriuretic peptide receptors, which lack the guanylyl cyclase domain, alter target cell function through G protein-coupled inhibition of membrane i adenylyl cyclase activity, and also serve to clear circulating natriuretic peptides. The expression of the natriuretic peptides and their receptors are subject to complex controls. Similar structural and regulatory diversity exists for the nitric oxide synthases. The three nitric oxide synthase genes are regulated by a variety of mechanisms ranging from alternative splicing and alternative promoter usage to complex post-translational controls. This review highlights the molecular diversity of the natriuretic peptides and nitric oxide synthases and explores recent insights into their regulation.
Introduction
renal, and immune cell function. The natriuretic peptides, their receptors, and the nitric oxide synthases share considThe discovery of atrial natriuretic peptide in 1981 by de erable commonality in that they function in vasodilator, Bold et al. [1] radically expanded the perception of the antihypertensive, and guanylate cyclase agonist pathways. heart as simply a mechanical pump to that of a neuroenAs expected from their central and potent roles in physidocrine organ. Likewise, the combined discoveries of ology ( Fig. 1 ), these gene families have evolved structural Ignarro, Murad and Furchgott (cited in Ref. [2] ) that a gas, and regulatory complexity over time. The present review nitric oxide (NO), formed and released by the vascular focuses on the molecular biology of the natriuretic peptide, endothelium, controlled vascular tone, transformed our natriuretic peptide receptor, and nitric oxide synthase thinking of the endothelium to its current conception as a genes and gene products and the regulatory controls on vital organ that senses and responds to changes in blood their synthesis and actions. flow. The natriuretic peptides are a group of structurally related but genetically distinct peptides that exert diverse actions on cardiovascular, renal, and endocrine function.
2. The natriuretic peptide family The natriuretic peptides have emerged as important contributors to the control of cardiovascular hemodynamics,
The natriuretic peptide family comprises four principal ventricular remodeling, and sodium and water balance. NO peptides whose prohormones are encoded by at least three is widely recognized as a critical cell signaling and host separate genes (Table 1) . This family includes atrial defense molecule with diverse actions on cardiovascular, natriuretic peptide (ANP), B-type natriuretic peptide (brain natriuretic peptide, BNP), C-type natriuretic peptide of the green Mamba snake, Dendroaspis angusticeps, and it contains the conserved disulfide ring structure [7] . The cDNA and gene structure of the human ortholog of DNP remains to be elucidated. ANP was originally identified in atrial myocardial extracts as a substance promoting natriuresis [1] . The isolation and cloning of human ANP soon followed. ANP is principally produced in the atria of normal adults, but it is also expressed in the ventricles during development [8, 9] and in hypertrophied ventricles [10] . ANP infusion in normal man promotes natriuresis, diuresis, and increases glomerular filtration rate [11] . ANP has also been shown to decrease plasma renin activity, plasma aldosterone, and plasma endothelin release in normal humans and in heart failure patients [12, 13] . The ANP precursor peptide (NPPA) and BNP precursor peptide (NPPB) genes reside in tandem on human chromosome 1p36.2. The NPPA gene (CNP), and urodilatin. Each natriuretic peptide family comprises three exons and two introns. Its mRNA encodes member shares a 17-amino acid disulfide ring struca precursor peptide, pro-ANP, of 126 amino acids, which is ture with a highly conserved sequence proteolytically cleaved to a 98-amino acid amino-terminal (FGXXXDRIGXXSGL). ANP and BNP are primarily fragment and a 28-amino acid carboxy-terminal fragment synthesized in the cardiac atria and ventricles, respectively, [14] . The carboxy-terminal fragment represents mature, circulate in the bloodstream, and directly modulate blood biologically active ANP [14] . Recent studies indicate that pressure and body fluid and electrolyte homeostasis. In corin, a cardiac serine protease, cleaves pro-ANP to ANP contrast, CNP is abundantly expressed in brain, but in a highly sequence-specific manner and may represent a vascular endothelium and other tissues also produce it.
(the) pro-ANP-converting enzyme [15] . Mice with targeted CNP circulates at very low levels and lacks potent disruption in the Nppa gene develop salt-sensitive hynatriuretic actions, but it possesses vasodilating and growthpertension [16] . inhibiting actions and may function in paracrine or auto-BNP was first purified from porcine brain [17] . Using crine roles. In distal tubules of the kidney, alternative the porcine cDNA as a screening probe, Seilhamer et al. cleavage of pro-ANP yields a 32-amino acid carboxyisolated and sequenced the BNP cDNA [18] . Its gene terminal peptide, termed urodilatin [3] . Urodilatin released consists of two exons and an intron and localizes approxifrom these cells binds to luminal receptors in the collecting mately 8 kb upstream of the NPPA gene on human duct, resulting in cGMP-dependent suppression of sodium chromosome 1p36. The NPPB gene encodes a 108-amino reabsorption. More recently, a fifth putative member of the acid pro-BNP, which is processed to a 32-amino acid natriuretic peptide family, related to Dendroaspis natmature peptide. Although expressed in brain, BNP is most riuretic peptide (DNP), has been reported to be expressed abundant in the cardiac ventricles. Its expression is inin human plasma and atrial myocardium [4] , to exert duced in this tissue in decompensated heart failure [19] . natriuretic actions [5] , to increase urinary and plasma BNP exerts many of the same actions as ANP on target cGMP, and to dilate coronary arteries [6] . The 38-amino organs. Mice with targeted disruption of BNP develop acid DNP peptide was originally isolated from the venom multifocal fibrotic lesions in the cardiac ventricles in the absence of systemic hypertension or ventricular hypertermed NPR-A) and NPR2 (also termed NPR-B) include trophy. Accordingly BNP is viewed as a cardiomyocytecytoplasmic tails that contain guanylate cyclase activity derived antifibrotic factor in vivo that may function as a and kinase homology regions. NPR3 (also termed NPR-C) local regulator of ventricular remodeling [20] .
[27] is homologous in its extracellular domain to NPR1 CNP was also originally isolated in porcine brain [21] , and NPR2, but contains a 37-amino acid cytoplasmic but immunoreactivity for this peptide has since been found domain that contains a G protein-activating sequence; in human vascular endothelial cells, kidney, reproductive moreover this receptor is devoid of kinase and guanylyl organs, and other tissues. Several studies have demoncyclase activities [28] . Studies in knockout mice have strated that CNP serves as a potent inhibitor of the confirmed that NPR3 serves as a 'clearance' receptor [29] , proliferation of smooth muscle cells [22] . CNP displays a clearing natriuretic peptides to effect local regulation. positive lusitropic effect associated with a negative inoSeveral laboratories have provided evidence that the NPR3 tropic effect in rat papillary muscles [23] . CNP infusion in receptor also mediates signal transduction either through normal man caused dose-dependent increases in natinhibition of adenylyl cyclase via Ga [30] or activation i22 riuresis, with less potency than ANP, and no effect on of phospholipase C via the bg-subunits of G and G [24] . The gene encoding C-type natriuretic encoding the single transmembrane domain resides in exon peptide (NPPC) is localized to human chromosome 2 [25] 7. The NPR1 gene product is abundantly expressed in the and contains two exons separated by an intron. The NPPC vasculature, kidneys, and adrenal glands. Its stimulation gene encodes a 126-residue CNP precursor peptide that is promotes vasorelaxation and natriuresis, and decreases processed to generate 22-and 53-amino acid peptides aldosterone synthesis. Mice lacking a functional NPR1 (human CNP-22 and human CNP-53, respectively) [26] .
gene exhibit hypertension and cardiac hypertrophy and CNP-53 represents an amino-terminal extension of the dilatation. Male mice additionally exhibit reduced testo-CNP-22 peptide. CNP-22 is more widely and abundantly sterone levels, experience sudden death before 6 months of expressed and is more potent that the C-53 peptide.
age [32, 33] , and are more susceptible to hypoxia-induced pulmonary hypertension [34] . Activation of the NPR1 guanylyl cyclase requires ANP binding to the extracellular domain and phosphorylation at up to six residues (S497, 3. Natriuretic peptide receptors T500, S502, S506, S510, and T513) [35] within its cytoplasmic region kinase homology domain. In addition, The natriuretic peptides signal through a group of cell recent studies have identified transcriptional mechanisms surface natriuretic peptide receptors (NPRs, through functional, and possibly physical, interactions of Similarly, the transcription factor GATA-5 together with NF-Y and Sp1 [36, 37] .
the coactivator p300 transactivates the ANP gene in NPR2 is a 1047-amino acid peptide that responds cardiomyocytes [44] . primarily to CNP. The cDNA and deduced amino acid a1-and b1-adrenergic agonists are known to upregulate sequences of human NPR2 have been described [38] .
ANP gene expression. Studies of the molecular control of NPR1 and NPR2 share 44% homology in the ligandthe gene indicate that responsiveness to a1-adrenergic binding region of the extracellular domain. The NPR2
agonists depends on occupation of the serum response gene comprises approximately 16.5 kb on human chromoelements at 2114 and 2406 bp and the Sp1-like sequence some 9p21-p12. It is composed of 22 exons. The gene is at 269 bp [45] . b-Adrenergic receptor-stimulated ANP strongly expressed in the brain, including the pituitary transcription in cardiac myocytes is predominantly megland, and may have a role in neuroendocrine regulation.
diated by activation of Akt and subsequent phosphorylaPhosphorylation of up to five residues (Ser-513, Thr-516, tion / inhibition of glycogen synthase kinase 3b [46] . Ser-518, Ser-523, and Ser-526) within the kinase homolNuclear hormone receptors also regulate ANP gene ogy domain appears to be critical for receptor activation expression. Glucocorticoids have been shown to upregulate [39] . Both NPR1 and NPR2 are extensively phos-ANP gene expression in target tissues. A glucocorticoid phorylated in resting cells, and receptor dephosphorylation receptor dimer binding to the glucocorticoid responsive correlates with ligand-induced homologous desensitization. element in intron 2 of the ANP gene has been shown to NPR3 interacts with all three natriuretic peptides in the transactivate the ANP gene in vitro. In contrast 1,25-order ANP.CNP.BNP [40] . Natriuretic peptides that are dihydroxyvitamin D3 represses ANP gene transcription bound by the receptor are internalized and degraded. The [47] . Recruitment of coactivators, including GRIP1, apcDNA encoding human NPR3 was cloned from human pears to be important for the hormone's suppressive placental and kidney cDNA libraries [27] . The NPR3 gene effects. Finally a 120-base pair region within the ANP resides on human chromosome 5p14-p13 and encodes a gene promoter contains hypoxia-responsive elements that 540-amino acid peptide. The mature NPR3 receptor exists might be responsible for the enhancement of ANP gene as homodimers linked by disulfide bonds. It is the most expression in atrial myocytes during hypoxic exposure widely and abundantly expressed natriuretic peptide re- [48] . ceptor, with a tissue distribution that includes most of the major endocrine glands, the lungs, kidney, and the vascular wall. NPR3 null mice exhibit a prolonged half-life of 4.2. BNP gene expression exogenous ANP, mild reductions in blood pressure, increased daily urinary output, and increased basal bone Synthesis and secretion of BNP, like ANP, are increased turnover coupled with bony deformities [29] .
in patients with congestive heart failure, in the early phase of acute myocardial infarction [49] , and in animal models of ventricular hypertrophy. Sustained increases in plasma 4. Regulation of the natriuretic peptide genes BNP concentrations are also correlated with enlargement, decreased contractility, and reduced compliance of the left 4.1. ANP gene expression ventricle in patients with congestive heart failure and myocardial infarction [50, 51] . The molecular regulation of The human ANP promoter contains numerous cis-ele-BNP differs from that of ANP. The regulatory regions in ments that govern cell specificity of expression and the proximal promoters of the human BNP and human responsiveness to physiological and pharmacological ANP genes share only 50% sequence similarity, although stimuli. Expression of the endogenous gene occurs almost both contain AP-1 binding sites, serum response elements exclusively in myocardial cells. Studies using human ANP (CArG / SRE), and GATA sites. The full-length human promoter-reporter gene constructs have sought to dis-BNP promoter exerts greater activity in ventricular than in tinguish molecular details of cell-specific expression. Garatrial myocytes, and it is inactive in fibroblasts. The distal mai et al. demonstrated repressor activity in the distal region of the BNP promoter contains both positive and (22593 to 21152) and proximal (2222) promoter that negative regulatory elements, with the region 2127 to prevents expression in non-myocardial cells. An E-box 240 conferring tissue specificity [52] . motif in the upstream repressor appears to be critical for A variety of stimuli have been shown to activate the repressor activity [41] . In addition, the cardiac homeobox BNP gene promoter in cardiac myocytes in vitro, including gene Csx / Nkx-2.5, binding to the Nkx-2.5 response mechanical strain and endothelin. The response to meelement-2 in the ANP promoter, has been shown to chanical strain depends on p38 MAPK activation and cooperate with GATA-4 in synergistically transactivating interaction of the transcription factor nuclear factor NF-kB the ANP gene [42] . In agreement with these findings, with three shear stress response elements (SSRE)-like transgenic mice overexpressing Csx / Nkx-2.5 exhibit structures in the proximal human BNP promoter [53] . dramatically enhanced ANP expression in their hearts [43] .
b-Adrenergic regulation of human BNP involves a Ga -activated pathway, Src, and Rac, targeting an M-CAT-like 5. Nitric oxide synthases element in the proximal human BNP promoter [54] . IL-1b has also been shown to be a transcriptional activator of the The NOS multigene family comprises three principal human BNP promoter. Recent studies suggest that IL1-b members (Table 3) : neuronal NOS (nNOS), inducible acts through multiple signaling pathways, including Ras, NOS (iNOS), and endothelial NOS (eNOS). A mitoRac, and p38 MAP kinase [55] . Cell-matrix interactions chondrial NOS has also been reported [66, 67] , but its also appear to be important for controlling BNP gene structure and regulation are not defined. The three major expression in vitro. Liang et al. [56] demonstrated that enzymes are subject to expressional control. nNOS and 21 dominant-negative inhibitors of integrin function supeNOS are inactive until intracellular Ca levels increase pressed strain-dependent BNP promoter activity in neonatsufficiently to maintain calmodulin binding. In contrast 21 al rat ventricular myocytes. The BNP gene is one of iNOS tightly binds calmodulin at basal intracellular Ca 21 several cardiac-specific genes (but alone among the natconcentrations, and thus has been viewed as a Ca / riuretic peptide genes [57] ) suppressed by the antineoplascalmodulin-independent enzyme. The genes and cDNAs tic agent doxorubicin [58] , which is known for its myocarencoding the three NOS isoforms have been structurally dial toxicity.
characterized. Mice bearing targeted deletions of each of the three major NOS isoforms, and an nNOS / eNOS 'double knockout,' have been established and have begun 4.3. CNP gene expression to be physiologically characterized. nNOS null mice exhibit hypertrophy of the pyloric sphincter, increased CNP gene expression in cultured endothelial cells is aggressive behavior in males, bladder-urethral sphincter enhanced by transforming growth factor-b [59] , IL-1a, dysfunction, and relative protection from ischemic neuro-IL-1b, tumor necrosis factor-a, and lipopolysaccharide logical events compared to wild-type mice [68] . The [60] . In contrast, oxidized-LDL [61] , insulin [62] , and principal phenotype of iNOS knockout mice is an invascular endothelial growth factor [63] inhibit endothelial creased susceptibility to infection with intracellular patho-CNP production. Studies in transgenic mice indicate that gens and less susceptibility to sepsis-induced hypotension cis-acting regulatory elements localized in the proximal [69] . The mice also exhibit impaired prostaglandin E2 4-kb 59-flanking sequence of the mouse CNP gene are production [70] . Targeted disruption of the iNOS gene necessary and sufficient to direct spatial and temporal completely abrogates the infarct-sparing effect of the late expression of the transgene in oligodendrocytes [64] . The phase of ischemic preconditioning [71] , attenuates neoinhuman CNP gene contains a GC-rich element, to which a tima formation after perivascular arterial injury [72] , and novel transcription factor TSF1 binds, that is required for protects kidneys against ischemic acute renal failure [73] . both constitutive and TGF-b responsive [65] transcription Studies in apoE-deficient mice bred with wild-type and of the gene.
iNOS 2 / 2 mice indicate that iNOS contributes to the size of atherosclerotic lesions in apoE-deficient mice, perhaps 6.2. iNOS through a direct effect at the site of the lesion [74] . eNOS knockout mice are hypertensive [75] , more vulnerable to
The human iNOS gene residing on chromosome 17cen-cerebral and myocardial ischemia than wild-type mice, and q11.2 contains 26 exons. Multiple transcription initiation exhibit a higher incidence of bicuspid aortic valves [76] .
sites and alternative splicing give rise to several forms of The mice also exhibit pulmonary hypertension with exon 1. In addition, cassette deletions give rise to four chronic, mild hypoxia [77] , impaired wound repair, dedistinct alternative splice variants of human iNOS mRNA. ficient growth factor-induced angiogenesis [78] , and markThese include deletions of exon 5 (resulting in a truncated edly decreased bleeding times [79] . Interestingly, ANP protein), exons 8 and 9 (encoding amino acids 242-235), expression is markedly upregulated in the eNOS 2 / 2 exons 9, 10, and 11 (encoding amino acids 289-427), and mice [80] .
exons 15 and 16 (encoding amino acids 604-678, including the FMN binding site) [87] . The iNOS lacking exons 8 and 9 exhibits a functional reductase domain but fails to 6. NOS gene products dimerize and to produce NO when heterologously expressed in cultured cells [88] . The translation and functions 6.1. nNOS of these variants in vivo remain to be established.
The human nNOS gene spans over 200 kb on chromo-6.3. eNOS some 12q24.2-q24.31. The major neuronal transcript comprises 29 exons and encodes a 160-kDa protein.
The eNOS gene is expressed in the endothelium of a Considerable structural and allelic diversity of nNOS variety of tissues, as well as in cardiac and myometrial transcripts arises from the use of alternative promoters and myocytes, platelets, and in airway epithelium. The human by the deletion or insertion of cassette exons via alternative eNOS gene on chromosome 7q36 contains 26 exons mRNA splicing. These gene products are principally spanning approximately 21 kb of genomic DNA and expressed in neurons, skeletal and vascular smooth muscle, encodes an mRNA of 4052 nucleotides. No alternative the macula densa segment, and bronchial and tracheal splice variants for this isoform have yet been characterized. epithelium. Two major transcriptional clusters -neuroSeveral allelic variants of the eNOS gene have been nal-and testis-specific -reside within the human nNOS identified and their association with human disease states gene. The neuronal cluster resides upstream of exon 2, in studied. Several of these genetic polymorphisms have been which the translation initiation codon resides. Nine alterreported as 'susceptibility genes' in various cardiovascular native first exons, each expressed from a unique 59-flankand pulmonary diseases. Yoshimura et al. [89] discovered a ing region, are spliced to a common second exon [81] , GT substitution in exon 7 (at position 894) in codon 298 of giving rise to the same protein with different 59-untransthe human eNOS gene, which alters the amino acid at this lated regions (UTR). The highly structured nNOS 59-UTRs residue from glutamate to aspartate. In vitro studies have contain cis RNA elements that modulate translational shown that this mutation results in susceptibility to cleavefficiency in vitro and in vivo [81] . The testis-specific age of the full-length protein into N-terminal 35-kDa and transcription cluster exists within intron 3 and gives rise to C-terminal 100-kDa fragments [90] . The Glu298Asp varan mRNA transcript comprised of two new 59 exons iant has been correlated with increased coronary spasm, spliced to exon 4 of nNOS. This testis-specific transcript myocardial infarction and essential hypertension in various encodes a smaller, 125-kDa protein with comparable populations. In the Cambridge Heart Antioxidant Study catalytic activity to that of full-length nNOS. Transcripts (CHAOS), Asp298 homozygosity correlated strongly with bearing deletions of exons 9 / 10, exon 10, exon 2 and exon coronary heart disease [91] . In separate studies of elderly 2 / 3 have been detected in human nNOS transcripts patients in Australia, no difference in the distribution of the [82, 83] , but it is unknown whether these mRNAs generate E298D alleles in relation to the presence of coronary artery functional proteins in vivo. The exon 2 deletion results in disease was observed [92] . Similarly, in a study of over the loss of the translation initiation site located within exon 750 white Australians undergoing coronary angiography, 2, and the apparent use of an atypical alternative start the mutation was unassociated with coronary artery discodon within exon 3 (UUG). Several cassette exon inserease, myocardial infarction, or with the number of sigtions have also been reported. A 102-bp insertion, encodnificantly stenosed arteries [93] . Finally, the frequency of ing 34 amino acids, between exons 16 and 17 (termed -m)
the Glu298Asp variant appears to be greater in women was identified in rat [84, 85] . This variant is principally with severe preeclampsia [94] . expressed in muscle complexed with dystrophin, and it is A T786C mutation in the 59-flanking region of eNOS coexpressed with nNOS in the pelvic plexus and bladder gene, which reduces eNOS promoter activity in vitro, was [84, 85] . A human variant of -m arising from insertion of an associated with coronary spasm in a Japanese population additional exon transcribed from intron 16 of the human [95, 96] . Replication protein A1 (RPA1), a single-stranded nNOS gene has since been described [86] .
DNA binding protein, appears to bind to and repress the mutated promoter sequence [97] . High numbers of CA amino acid protein termed PIN (for 'protein inhibitor of') repeats in intron 13 of the human eNOS gene are also binds to the N-terminus of nNOS and inhibits its activity associated with an excess risk of coronary artery disease [111, 112] . The molecular chaperone Hsp90 has been [98] , and variable repeats in intron 4 (intron 4b / a polyshown to complex with nNOS and to activate NO promorphism) have been reported to be involved in smokingduction [113] . Inhibition of Hsp90 by geldanamycin causes dependent coronary artery disease [95, 99] .
the loss of protein in cells. Ubiquitination and proteasomal degradation appears to be critical in removing non-functional monomers in vivo [114] .
Regulation of NOS isoforms
7.2. iNOS regulation 7.1. nNOS regulation A variety of transcriptional and post-transcriptional Originally, nNOS was thought to be a constitutively mechanisms regulate iNOS expression and activity, includexpressed enzyme, but it is now known that nNOS is ing changes in iNOS gene transcription, mRNA stability, induced by a variety of physiologic and pathological translation and degradation, substrate and cofactor binding stimuli. The neuronal transcriptional cluster of the human and availability, and dimerization. The murine iNOS nNOS gene contains potential binding sites for a number of promoter has been most extensively studied. Structuretranscription factors, including AP-2, NF-kB, CREB, and function studies of the murine iNOS promoter have Ets [82] . Studies of the promoter activity of this region in demonstrated that the region 248 to 2209 serves as a core neuronal and fibroblast cell lines revealed an important promoter module [115, 116] . Several response elements role for Oct-2 in transactivating the downstream (desighave been shown to be functionally active, including kB nated '5.1') promoter [100] . The upstream promoter sites [117] , a binding site for ESE-1 (a novel member of (designated '5'2') confers inducibility to nerve growth the ETS transcription factor family) [118] , a hypoxiafactor [101] . Most recently, two CREB sites within the responsive enhancer element [119] , a novel LPS response 59-UTR of mouse nNOS exon 2 have been shown to be element to which an Oct-1-like protein binds [120] , a functionally active in cortical neurons [102] . The corollary C / EBP box [121] , an IFN regulatory factor-1 (IRF-1) site regulatory region in the human nNOS gene has not been [122] , two sequential IFN-stimulated response elements, established. The human testis transcriptional cluster also and an IFN-g-activated site (GAS) [123] . SAPK / JNK and contains potential cis-regulatory elements [103] , but no p38a MAP kinase signaling cascades are necessary for the functional characterization of this region has yet been IL-1b-induced expression of iNOS and production of NO published.
in renal mesangial cells [124] . In contrast to these stimulatSeveral serine / threonine kinases have been shown to ory mechanisms, peroxisome proliferator-activated phosphorylate nNOS. Phosphorylation of purified nNOS receptor-g inhibition of the LPS and IFN-g induction of 21 by protein kinases A, G, or C, or Ca / calmodulinthe iNOS promoter is achieved partially through antagonizdependent protein kinase reduces catalytic activity, whereing the activities of NF-kB, AP-1, and STAT1 [125] . as calcineurin-mediated dephosphorylation enhances cataTranscriptional regulation of the human iNOS promoter / lytic activity [104] . AMP-activated protein kinase inenhancer differs markedly from its rodent counterparts. In creases nNOS phosphorylation in human skeletal muscle, contrast to murine iNOS, cytokine-enhancer elements in but its effects on nNOS activity are unknown [105] .
the human iNOS promoter / enhancer localize to sites far Further studies are needed to determine the role and upstream of the promoter module. An NF-kB motif at regulation of nNOS phosphorylation in intact cells.
25.8 kb was required for cytokine-induced promoter Protein-protein interactions help to regulate the spatial activity, while three neighboring NF-kB sites elicited a distribution and activity of nNOS in various cell types. synergistic effect. p38-and ERK-dependent pathways, Calmodulin serves as an allosteric activator for each of the acting through AP-1 elements in the human iNOS promot-NOS isozymes. The N-terminus of nNOS contains a PDZ er, also confer inducibility to cytokines and LPS / IFN-g domain that associates with a1-syntrophin [106] , post- [126] . synaptic density proteins PSD-93 and PSD-95 [107] , and
As with nNOS, interactions with heterologous proteins the muscle isoform of phosphofructokinase (PFK-M). An appear to regulate iNOS activity. Murine macrophages additional protein, CAPON (for carboxy-terminal PDZ express a 110-kDa protein that interacts with the amino ligand of nNOS), binds nNOS in neurons and may terminus of iNOS, termed NOS-associated protein-110 compete with PDZ-95 for nNOS association in brain [108] . kDa (NAP110). NAP110 was shown to inhibit iNOS nNOS also interacts with caveolin-3 in skeletal muscle, catalytic activity by preventing dimerization [127] . Kalirin where it appears to comprise a component of the associates with iNOS in vitro and in vivo and inhibits dystrophin complex [109, 110] . Synthetic peptides correiNOS activity by preventing the formation of iNOS sponding to regions of caveolins 1 and -3 inhibited the homodimers [128] . iNOS may also complex with caveolin catalytic activity of recombinant nNOS [109] . An 89-3 in skeletal muscle [129] .
Changes in mRNA stability of the iNOS gene have also heart, lung, kidney, liver, spleen, and brain. The mibeen implicated in the control of iNOS gene expression. crovasculature, with the exception of the vasa recta of the The 39-UTR of the human iNOS mRNA contains four renal medulla, showed no eNOS transgene expression. AUUUA motifs and one AUUUUA motif. The embryonic Similarly cardiac myocytes, skeletal muscle, and smooth lethal abnormal vision (ELAV)-like protein HuR was muscle of both vascular and nonvascular sources failed to found to bind with high affinity to the AU-rich elements of demonstrate transgene expression [143] . the iNOS 39-UTR and to stabilize this mRNA [130] . In A number of stimuli alter eNOS gene expression. other examples, IL-1b stimulates iNOS expression in Chronic hypoxia [144] and heart failure [145] are associpancreatic b-cells in part by stabilizing iNOS mRNA ated with changes in eNOS expression in lung and heart, through a PKCd-dependent mechanism [131] . b-Adrenrespectively. Shear stress [146] , tumor necrosis factor-a, ergic stimulation enhances IL-1b induction of iNOS in lysophosphatidylcholine (LPC), oxidized LDL, PDGF, cardiac fibroblasts by stabilizing the iNOS message [132] .
bFGF, VEGF, TGF-b1, oxidative stress, cyclosporine A, Tetrahydrobiopterin, an allosteric cofactor of iNOS, stabiand angiotensin II (reviewed in Ref. [147] ) have all been lizes the transcript in rat vascular smooth muscle cells shown to influence the level of eNOS gene product in 21 [133] . In contrast, increased Ca concentrations reduced cultured endothelial cells. LPC is a potent activator of iNOS mRNA half-life in human articular chondrocytes eNOS expression. LPC is a major component of oxidized [134] . Interestingly ANP has potent autocrine effects on low density lipoproteins and is abundant in atherosclerotic NO production in macrophages. ANP specifically induced blood vessels. LPC enhances Sp1-dependent eNOS proacceleration of iNOS mRNA decay and reduced binding moter activity by a pertussis toxin-sensitive, Ras-indepenactivity of NF-kB, abrogating LPS induction of the iNOS dent pathway that involves a cascade of PI-3Kg/ Jak2, gene [135] . Tyrosine kinases and phosphatases appear to MEK-1, and ERK1 / 2 [148] . Estradiol has been shown to be involved in post-translational modification of iNOS as activate human eNOS promoter activity, in part via activawell, and may potentially play a role in modulating the tion of the transcription factor Sp1, in cultured endothelial functional activity of the enzyme [136, 137] .
cells [137] . NF-1 binding to a putative TGF-b1 promoter response element is important for TGF-b1 transactivation 7.3. eNOS regulation of the bovine eNOS gene in endothelial cells [149] . Similarly, a PDGF response element between 2744 and The eNOS gene on human chromosome 7q36 spans |21 21600 of the human eNOS gene appears to be important kb and contains 26 exons. The 'TATA-less' promoter / for transactivation of the eNOS gene in endothelial cells enhancer region includes a CCAAT box, several half- [150] . In contrast to these activating stimuli, glucocorpalindrome sequences for estrogen response elements, a ticoids reduced the activity of 3.5-kb human eNOS promotshear stress response element, and potential binding sites er-reporter gene construct to approximately 70% by for Sp1, AP-1, cAMP response element (CRE), GATA, decreasing GATA binding activity [151] . nuclear factor 1 (NF-1), g-interferon response element Changes in mRNA stability affect eNOS mRNA expres-(g-IRE), and NF-kB. Mutational analysis of the eNOS sion in several settings. The 39-UTR of eNOS mRNA promoter / enhancer has established that an upstream Sp1 contains an adenine-uridine (A1U)-rich region with two binding site, a GATA site at position 2230, and the PEA3 AUUUA pentamers in the 39 end of 39-UTR and a C-rich site at 226 are essential for basal promoter activity in region in the 59 half of the 39-UTR. Studies in TNFatransfected endothelial cells [138, 139] . In another study, treated endothelial cells demonstrated that a 60-kDa endotwo positive regulatory domains at 2104 / 295 and 2144 / thelial cytosolic protein was induced and bound to the 2115, to which Ets family members, Sp1, variants of Sp3, C-rich region of the 39-UTR. This was associated with MAZ, and YY1 bound, were important for human eNOS destabilization of eNOS mRNA [152] . In other work, a promoter activity in endothelial cells [140] . Sp1 binding to 51-kDa cytoplasmic protein was found to bind a 43-these proximal elements and transactivation of eNOS nucleotide sequence in the eNOS 39-UTR and alter eNOS appears to be regulated in a complex manner that involves mRNA stability during endothelial cell growth [153] . post-translational Sp1 phosphorylation and dephosphorylaOxidant stress, induced by hydrogen peroxide, increases tion via casein kinase 2 and protein serine / threonine eNOS expression through transcriptional activation and phosphatase 2A [141] . A third positive regulatory domain stabilization of eNOS mRNA in cultured endothelial cells in the eNOS promoter was identified 4.9 kb upstream from [154] . Similarly, HMG-CoA reductase inhibitors, by the transcription start site. Several transcription factors, blocking the geranylgeranylation of the GTPase Rho, including MZF-like, AP-2, Sp-1-related and Ets-related prolong eNOS mRNA half-life [155] . factors, were critical for the function of this enhancer in Acylation and phosphorylation of eNOS regulate both endothelial cells [142] . Finally, studies in mice transgenic activity and subcellular localization of the enzyme. Nfor a promoter-reporter construct containing 5.2 kb of the Myristoylation and palmitoylation are required for efficient native murine eNOS promoter demonstrated transgene eNOS targeting to caveolae of the endothelial cell memexpression in large and medium-sized blood vessels of the brane [156, 157] and appear to facilitate optimal NO release. At resting intracellular calcium concentrations, will be increasingly exploited in the diagnosis, risk assesseNOS is tonically inhibited through a stable interaction ment, and therapy of cardiovascular and cardiorenal diswith caveolins [110, 158, 159] . Agonists, such as bradyeases. kinin, increased vascular flow, or fluid shear stress, raise 21 intracellular Ca concentrations and cause calmodulin to bind and caveolin to dissociate from eNOS resulting in an Acknowledgements activated eNOS-calmodulin complex. The molecular chaperone Hsp90 appears to facilitate the actions of Work in the author's laboratory is supported by grants calmodulin on eNOS dissociation from caveolins [160] . DK47981, DK50745, and GM20529 from the National Inhibition of the enzyme also occurs through interactions
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